Financial Report: Lilly

Lilly
 
3Q Revenues: $5.8 billion (+6%)

3Q Earnings: $1.2 billion (-9%)

YTD Revenues: $17.3 billion (+4%)

YTD Earnings: $4.0 billion (+21%)

Comments: Revenue in the U.S. increased 11% to $3.3 billion in the quarter, while revenue outside the U.S. was flat at $2.5 billion, impacted by the depreciation of the Japanese yen. Growth was driven by Humalog, up 7% to $616 million, Alimta, up 7% to $690.5 million, and Forteo, up 6% to $306.7 million. Zyprexa sales were down 26% to $278.7 million and Cymbalta was down 11% to $1.4 billion, due to generic competition. Animal Health revenue was up 11% to $530.3 million.